Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 18;8(11):512. doi: 10.3390/biomedicines8110512

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of ezetimibe on the sizes of adipocytes, markers of inflammation, and genes involved in lipogenesis, lipolysis, and β-oxidation. (a) The effects of ezetimibe on the sizes of adipocytes were compared using two-sample t-test for a total of 1,300 adipocytes (n = 100 per animal). The sizes of the adipocytes were markedly reduced in the ezetimibe group, compared to those in the control group (p < 0.001). (b) The effects of ezetimibe on markers of inflammation: (upper panel) pro-inflammatory cytokines and (lower panel) anti-inflammatory cytokines. (c) LPL, (d) Lipin1, (e) Perilipin, (f) PEPCK, (g) ATGL, (h) PDK2, and (i) LCAD. Compared using the Wilcoxon-Mann-Whitney U test; * p < 0.05. LPL; lipoprotein lipase, PEPCK; phosphoenolpyruvate carboxykinase, ATGL; adipose triglyceride lipase, PDK2; pyruvate dehydrogenase kinase-2, LCAD; long-chain acyl-CoA dehydrogenase.